United States · Bill · S
S. 6 (117th)
Biosimilar Red Tape Elimination Act
Introduced
17 November 2022
Last action
—
Status
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sponsors
—
Subjects
Discovery layer
Source updated
21 April 2025
Summary
Biosimilar Red Tape Elimination Act This bill removes and otherwise modifies certain requirements related to the approval of biosimilars, such as prohibiting the Food and Drug Administration from requiring studies that assess the risks of switching between the biosimilar and the reference biologic.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
3 official files
Introduced in Senate (text)
Introduced in Senate · EN · 17 November 2022
Introduced in Senate (PDF)
Introduced in Senate · EN · 17 November 2022
Introduced in Senate
summary · EN · 17 November 2022
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/117th-congress/senate-bill/6
- Open data entity: https://api.congress.gov/v3/bill/117/s/6